Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.

Igho J OnakpoyaJoseph J LeeKamal R MahtaniJeffrey K AronsonCarl J Heneghan

Published in: British journal of clinical pharmacology (2020)

Naltrexone-bupropion significantly reduces body weight by a small amount but significantly increases the risk of adverse events. A rigorous process of postmarketing surveillance is required.

Keyphrases

body weight
alcohol use disorder
metabolic syndrome
insulin resistance
weight loss
public health
type diabetes
weight gain
high fat diet induced
adverse drug
clinical trial
double blind
adipose tissue
skeletal muscle
drug administration
electronic health record